ACC 2021 Ablation-based rhythm control and rate control showed no statistically significant differences in the RAFT-AF trial for the primary outcome of all-cause mortality and HF events in patients with HF and high burden AF.
ACC 2021 REHAB-HF showed that individualized physical rehabilitation intervention, compared to usual care, resulted in significant improvements in physical function, frailty status, quality of life, and depression in older patients with ADHF.
ACC 2021 A short summary of the PARADISE-MI trial with sacubitril/valsartan compared to ramipril in MI patients is provided by prof. Pfeffer.
Low gestational age at birth (<37 weeks) was associated with an increased risk for the development of HF into adulthood. The lower the gestational age of an infant at birth, the higher the risk for new-onset HF.
This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.
Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.
Findings of a study using real-world data from REGARDS showed that prevalence of polypharmacy, defined as ≥10 medications, is high in older patients hospitalized for HF.
This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.
AHA 2020 Prof. Pfeffer gives his perspective on therapeutic options for HFrEF patients, as an increasing number of drugs have demonstrated beneficial effects in this patient population.
AHA 2020 Prof. Ponikowski presents the details of the AFFIRM-AHF trial, in which the effect of administration of IV ferric carboxymaltose shortly before discharge on clinical outcomes was examined in patients with acute HF and iron deficiency.
AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.
HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.